MALDI TOF imaging mass spectrometry in clinical pathology: a valuable tool for cancer diagnostics (review).
Identifieur interne : 000276 ( PubMed/Corpus ); précédent : 000275; suivant : 000277MALDI TOF imaging mass spectrometry in clinical pathology: a valuable tool for cancer diagnostics (review).
Auteurs : Jörg Kriegsmann ; Mark Kriegsmann ; Rita CasadonteSource :
- International journal of oncology [ 1791-2423 ] ; 2015.
English descriptors
- KwdEn :
- Biomarkers, Tumor (analysis), Brain (metabolism), Freezing, Humans, Immunohistochemistry (methods), Neoplasms (diagnosis), Neoplasms (metabolism), Neoplasms (pathology), Paraffin Embedding, Pathology, Clinical (methods), Prognosis, Proteins (analysis), Specimen Handling (methods), Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization (methods), Tissue Array Analysis, Tissue Fixation (methods).
- MESH :
- chemical , analysis : Biomarkers, Tumor, Proteins.
- diagnosis : Neoplasms.
- metabolism : Brain, Neoplasms.
- methods : Immunohistochemistry, Pathology, Clinical, Specimen Handling, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Tissue Fixation.
- pathology : Neoplasms.
- Freezing, Humans, Paraffin Embedding, Prognosis, Tissue Array Analysis.
Abstract
Matrix-assisted laser desorption/ionization (MALDI) time-of-flight (TOF) imaging mass spectrometry (IMS) is an evolving technique in cancer diagnostics and combines the advantages of mass spectrometry (proteomics), detection of numerous molecules, and spatial resolution in histological tissue sections and cytological preparations. This method allows the detection of proteins, peptides, lipids, carbohydrates or glycoconjugates and small molecules.Formalin-fixed paraffin-embedded tissue can also be investigated by IMS, thus, this method seems to be an ideal tool for cancer diagnostics and biomarker discovery. It may add information to the identification of tumor margins and tumor heterogeneity. The technique allows tumor typing, especially identification of the tumor of origin in metastatic tissue, as well as grading and may provide prognostic information. IMS is a valuable method for the identification of biomarkers and can complement histology, immunohistology and molecular pathology in various fields of histopathological diagnostics, especially with regard to identification and grading of tumors.
DOI: 10.3892/ijo.2014.2788
PubMed: 25482502
Links to Exploration step
pubmed:25482502Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">MALDI TOF imaging mass spectrometry in clinical pathology: a valuable tool for cancer diagnostics (review).</title>
<author><name sortKey="Kriegsmann, Jorg" sort="Kriegsmann, Jorg" uniqKey="Kriegsmann J" first="Jörg" last="Kriegsmann">Jörg Kriegsmann</name>
<affiliation><nlm:affiliation>MVZ for Histology, Cytology and Molecular Diagnostics, Trier, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kriegsmann, Mark" sort="Kriegsmann, Mark" uniqKey="Kriegsmann M" first="Mark" last="Kriegsmann">Mark Kriegsmann</name>
<affiliation><nlm:affiliation>Institute for Pathology, University of Heidelberg, Heidelberg, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Casadonte, Rita" sort="Casadonte, Rita" uniqKey="Casadonte R" first="Rita" last="Casadonte">Rita Casadonte</name>
<affiliation><nlm:affiliation>Proteopath GmbH, Trier, Germany.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25482502</idno>
<idno type="pmid">25482502</idno>
<idno type="doi">10.3892/ijo.2014.2788</idno>
<idno type="wicri:Area/PubMed/Corpus">000276</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000276</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">MALDI TOF imaging mass spectrometry in clinical pathology: a valuable tool for cancer diagnostics (review).</title>
<author><name sortKey="Kriegsmann, Jorg" sort="Kriegsmann, Jorg" uniqKey="Kriegsmann J" first="Jörg" last="Kriegsmann">Jörg Kriegsmann</name>
<affiliation><nlm:affiliation>MVZ for Histology, Cytology and Molecular Diagnostics, Trier, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kriegsmann, Mark" sort="Kriegsmann, Mark" uniqKey="Kriegsmann M" first="Mark" last="Kriegsmann">Mark Kriegsmann</name>
<affiliation><nlm:affiliation>Institute for Pathology, University of Heidelberg, Heidelberg, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Casadonte, Rita" sort="Casadonte, Rita" uniqKey="Casadonte R" first="Rita" last="Casadonte">Rita Casadonte</name>
<affiliation><nlm:affiliation>Proteopath GmbH, Trier, Germany.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">International journal of oncology</title>
<idno type="eISSN">1791-2423</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Biomarkers, Tumor (analysis)</term>
<term>Brain (metabolism)</term>
<term>Freezing</term>
<term>Humans</term>
<term>Immunohistochemistry (methods)</term>
<term>Neoplasms (diagnosis)</term>
<term>Neoplasms (metabolism)</term>
<term>Neoplasms (pathology)</term>
<term>Paraffin Embedding</term>
<term>Pathology, Clinical (methods)</term>
<term>Prognosis</term>
<term>Proteins (analysis)</term>
<term>Specimen Handling (methods)</term>
<term>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization (methods)</term>
<term>Tissue Array Analysis</term>
<term>Tissue Fixation (methods)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Biomarkers, Tumor</term>
<term>Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Brain</term>
<term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Immunohistochemistry</term>
<term>Pathology, Clinical</term>
<term>Specimen Handling</term>
<term>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</term>
<term>Tissue Fixation</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Freezing</term>
<term>Humans</term>
<term>Paraffin Embedding</term>
<term>Prognosis</term>
<term>Tissue Array Analysis</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Matrix-assisted laser desorption/ionization (MALDI) time-of-flight (TOF) imaging mass spectrometry (IMS) is an evolving technique in cancer diagnostics and combines the advantages of mass spectrometry (proteomics), detection of numerous molecules, and spatial resolution in histological tissue sections and cytological preparations. This method allows the detection of proteins, peptides, lipids, carbohydrates or glycoconjugates and small molecules.Formalin-fixed paraffin-embedded tissue can also be investigated by IMS, thus, this method seems to be an ideal tool for cancer diagnostics and biomarker discovery. It may add information to the identification of tumor margins and tumor heterogeneity. The technique allows tumor typing, especially identification of the tumor of origin in metastatic tissue, as well as grading and may provide prognostic information. IMS is a valuable method for the identification of biomarkers and can complement histology, immunohistology and molecular pathology in various fields of histopathological diagnostics, especially with regard to identification and grading of tumors.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25482502</PMID>
<DateCreated><Year>2015</Year>
<Month>01</Month>
<Day>21</Day>
</DateCreated>
<DateCompleted><Year>2015</Year>
<Month>09</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised><Year>2015</Year>
<Month>11</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1791-2423</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>46</Volume>
<Issue>3</Issue>
<PubDate><Year>2015</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>International journal of oncology</Title>
<ISOAbbreviation>Int. J. Oncol.</ISOAbbreviation>
</Journal>
<ArticleTitle>MALDI TOF imaging mass spectrometry in clinical pathology: a valuable tool for cancer diagnostics (review).</ArticleTitle>
<Pagination><MedlinePgn>893-906</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3892/ijo.2014.2788</ELocationID>
<Abstract><AbstractText>Matrix-assisted laser desorption/ionization (MALDI) time-of-flight (TOF) imaging mass spectrometry (IMS) is an evolving technique in cancer diagnostics and combines the advantages of mass spectrometry (proteomics), detection of numerous molecules, and spatial resolution in histological tissue sections and cytological preparations. This method allows the detection of proteins, peptides, lipids, carbohydrates or glycoconjugates and small molecules.Formalin-fixed paraffin-embedded tissue can also be investigated by IMS, thus, this method seems to be an ideal tool for cancer diagnostics and biomarker discovery. It may add information to the identification of tumor margins and tumor heterogeneity. The technique allows tumor typing, especially identification of the tumor of origin in metastatic tissue, as well as grading and may provide prognostic information. IMS is a valuable method for the identification of biomarkers and can complement histology, immunohistology and molecular pathology in various fields of histopathological diagnostics, especially with regard to identification and grading of tumors.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kriegsmann</LastName>
<ForeName>Jörg</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>MVZ for Histology, Cytology and Molecular Diagnostics, Trier, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kriegsmann</LastName>
<ForeName>Mark</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Institute for Pathology, University of Heidelberg, Heidelberg, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Casadonte</LastName>
<ForeName>Rita</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Proteopath GmbH, Trier, Germany.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2014</Year>
<Month>12</Month>
<Day>04</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Greece</Country>
<MedlineTA>Int J Oncol</MedlineTA>
<NlmUniqueID>9306042</NlmUniqueID>
<ISSNLinking>1019-6439</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011506">Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005615" MajorTopicYN="N">Freezing</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016612" MajorTopicYN="N">Paraffin Embedding</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010338" MajorTopicYN="N">Pathology, Clinical</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013048" MajorTopicYN="N">Specimen Handling</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019032" MajorTopicYN="N">Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D046888" MajorTopicYN="N">Tissue Array Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016707" MajorTopicYN="N">Tissue Fixation</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year>
<Month>08</Month>
<Day>06</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2014</Year>
<Month>11</Month>
<Day>04</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2014</Year>
<Month>12</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>12</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2015</Year>
<Month>9</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">25482502</ArticleId>
<ArticleId IdType="doi">10.3892/ijo.2014.2788</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Rhénanie/explor/UnivTrevesV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000276 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000276 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Rhénanie |area= UnivTrevesV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:25482502 |texte= MALDI TOF imaging mass spectrometry in clinical pathology: a valuable tool for cancer diagnostics (review). }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25482502" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a UnivTrevesV1
![]() | This area was generated with Dilib version V0.6.31. | ![]() |